Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B - Authors' reply

Affiliations

¹ Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan; Division of Gastroenterology and Hepatology, E-Da Hospital, Kaohsiung, Taiwan; School of Medicine, I-Shou University, Kaohsiung, Taiwan.
² Division of Gastroenterology and Hepatology, Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, CA 94304, USA. Electronic address: mindiehn@stanford.edu.

Comment

Cheng-Hao Tseng et al. Lancet Gastroenterol Hepatol. 2021 Feb.

. 2021 Feb;6(2):87-88.

doi: 10.1016/S2468-1253(20)30395-2.

¹ Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan; Division of Gastroenterology and Hepatology, E-Da Hospital, Kaohsiung, Taiwan; School of Medicine, I-Shou University, Kaohsiung, Taiwan.
² Division of Gastroenterology and Hepatology, Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, CA 94304, USA. Electronic address: mindiehn@stanford.edu.

No abstract available

Comment on

Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Tseng CH, et al. Lancet Gastroenterol Hepatol. 2020 Dec;5(12):1039-1052. doi: 10.1016/S2468-1253(20)30249-1. Epub 2020 Sep 30. Lancet Gastroenterol Hepatol. 2020. PMID: 33007228
Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B.
Choi WM, Choi J, Wong GL, Han S, Lim YS. Choi WM, et al. Lancet Gastroenterol Hepatol. 2021 Feb;6(2):87. doi: 10.1016/S2468-1253(20)30372-1. Lancet Gastroenterol Hepatol. 2021. PMID: 33444532 No abstract available.